Navigation Links
Bionovo Reports Third Quarter 2008 Financial Results
Date:11/3/2008

al dryness,

over other treatments. The Company expects to begin human clinical

trials for VG101 late in 2008 or early in 2009.

"The third quarter of the year continued the positive scientific progress for Bionovo," said Dr. Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "After much preparation and discussion with the FDA and our advisors, we are now poised to begin the next phase of clinical testing for our portfolio of women's health and oncology drug candidates. We are also continuing promising discussions with potential pharmaceutical partners."

"With over seventeen million dollars in cash, cash equivalents and short- term investments, and a lower than industry clinical trial cost profile, we are poised to progress our lead drug candidates through these challenging economic times," added Tom Chesterman, Bionovo's Senior Vice President and Chief Financial Officer. "Given our current plans and expectations, this funding will be sufficient for at least the next 12 months"

A full financial report on Form 10-Q is expected to be filed by Tuesday, November 4, 2008.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.b
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... June 17, 2010 An independent study has revealed,that Irish ... and consistent than a leading group of,international hypertension experts. , ... Conducted by the ... numerous blood pressure readings taken over a,24-hour period (known as ,Ambulatory Blood ...
... LEIDEN, The Netherlands and SEATTLE ... leader in the development of innovative products for,hemostasis and ... agreement with CSL Behring for the clinical and commercial ... Fibrocaps(TM).,CSL Behring is a leader in the plasma protein ...
... (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced ... Healthcare Conference in Boston on Wednesday, June 23, 2010 ... , , ... online from the investor relations page of the Company,s Web site at ...
Cached Biology Technology:Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 2Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 3ProFibrix and CSL Behring Enter Into Fibrinogen and Thrombin Supply Agreement 2Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference 2
(Date:7/9/2014)... Bacterial infections usually announce themselves with pain and fever but ... are those that are sneaky and hard to beat. Now, ... the form of tiny DNA pyramids. Published in the journal ... the nanopyramids can flag bacteria and kill more of them ... note that some infectious pathogens can lie in wait, undetectable ...
(Date:7/9/2014)... be on the verge of an economy driven by methane, ... coal and is undergoing a production boom. It has poised ... research is casting serious doubts over just how climate-friendly it ... News (C&EN), the weekly news magazine of the American ... correspondent at C&EN, explains that when burned as a fuel ...
(Date:7/9/2014)... To completely and systematically archive this body of ... in the life sciences spend a quarter of ... survey of 70 people working in biology laboratories ... Technology FIT in Sankt Augustin. Many of those ... structured approach to data collection in their workplace. ...
Breaking Biology News(10 mins):Managing the data jungle 2Managing the data jungle 3
... important techniques developed in atomic physics over the past few ... atoms and ions at temperatures just above absolute zero. Scientists ... that captured ions can also be cooled through contact with ... traps in a stable condition for longer periods of time. ...
... are sand and lakes are flats of dried mud. Are ... Earth, a planet where water covers some 70 percent of ... available to nourish life here? Scientists funded by the ... Systems (CNH) program are finding new answers. NSF-supported CNH ...
... NC The question of how life began on a ... recent mathematical research sheds light on a possible mechanism by ... soup that existed on the early Earth. Researchers have ... have gotten its start, even before the first genes or ...
Cached Biology News:Scientists from Bangalore and Mainz develop new methods for cooling of ions 2Water resources management and policy in a changing world: Where do we go from here? 2Water resources management and policy in a changing world: Where do we go from here? 3Model sheds light on the chemistry that sparked the origin of life 2
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
Biology Products: